Peter C. Van Den Akker

Groningen, GR 9700RB, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 59 publications

Meta-analysis of adverse events in clinical studies with antisense oligonucleotide therapies.

Meta-analysis of adverse events in clinical studies with antisense oligonucleotide therapies.

Journal: Molecular therapy. Nucleic acids

Published: July 01, 2026

The Economic Burden of Epidermolysis Bullosa: A Scoping Review.

The Economic Burden of Epidermolysis Bullosa: A Scoping Review.

Journal: Dermatology (Basel, Switzerland)

Published: February 01, 2026

Classifying novel DSG1 variants on disease severity in SAM syndrome and palmoplantar keratoderma.

Classifying novel DSG1 variants on disease severity in SAM syndrome and palmoplantar keratoderma.

Journal: Journal of dermatological science

Published: October 17, 2025

Novel ATP2C1 genetic variants in a Dutch cohort of patients with Hailey-Hailey disease.

Novel ATP2C1 genetic variants in a Dutch cohort of patients with Hailey-Hailey disease.

Journal: Journal of dermatological science

Published: June 13, 2025

Recessive epidermolysis bullosa simplex due to EXPH5 variants: case series of a rare subtype with multiple faces.

Recessive epidermolysis bullosa simplex due to EXPH5 variants: case series of a rare subtype with multiple faces.

Journal: The British journal of dermatology

Published: April 30, 2025

Long-read sequencing cracks unsolved cases and further improves genome diagnostics in epidermolysis bullosa.

Long-read sequencing cracks unsolved cases and further improves genome diagnostics in epidermolysis bullosa.

Journal: Journal of dermatological science

Published: April 01, 2025

SOX2 Is a Potential Diagnostic Biomarker and Anticancer Target in Cutaneous Squamous Cell Carcinoma in Dystrophic Epidermolysis Bullosa: A Case Series Study.

SOX2 Is a Potential Diagnostic Biomarker and Anticancer Target in Cutaneous Squamous Cell Carcinoma in Dystrophic Epidermolysis Bullosa: A Case Series Study.

Journal: JID innovations : skin science from molecules to population health

Published: February 11, 2025

Core outcome domain sets for clinical trials in epidermolysis bullosa - a COSEB protocol to achieve consensus on "what" to measure.

Core outcome domain sets for clinical trials in epidermolysis bullosa - a COSEB protocol to achieve consensus on "what" to measure.

Journal: Trials

Published: October 15, 2024

Identifying high-risk melanoma patients: The importance of acquiring a detailed family history.

Identifying high-risk melanoma patients: The importance of acquiring a detailed family history.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: May 20, 2024

Towards a roadmap for COSEB: the next steps in harmonization of outcomes for epidermolysis bullosa.

Towards a roadmap for COSEB: the next steps in harmonization of outcomes for epidermolysis bullosa.

Journal: The British journal of dermatology

Published: April 02, 2024

Navigating the diagnostic journey of epidermolysis bullosa: a qualitative study of the lived experiences and needs of parents and patients.

Navigating the diagnostic journey of epidermolysis bullosa: a qualitative study of the lived experiences and needs of parents and patients.

Journal: The British journal of dermatology

Published: October 19, 2023

Epidermal growth factor receptor inhibition leads to cellular phenotype correction of DSP-mutated keratinocytes.

Epidermal growth factor receptor inhibition leads to cellular phenotype correction of DSP-mutated keratinocytes.

Journal: Experimental dermatology

Published: October 18, 2023

Showing 1-12 of 59

Last Updated: 09/26/2026